Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

Journal of Medical Economics

Volumn 15, Issue 4, 2012, Pages 776-785

  Deitelzweig, Steve ^a   Amin, Alpesh ^b   Jing, Yonghua ^c   Makenbaeva, Dinara ^c   Wiederkehr, Daniel ^d   Lin, Jay ^e   Graham, John ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e Novosys Health   (United States)

Author keywords

Atrial fibrillation; Medical cost reductions; Novel oral anticoagulants; Stroke prevention

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST CONTROL; ENDPOINT DETERMINATION; HEALTH EXPENDITURES; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THIOPHENES; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84862549811     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.680555     Document Type: Article

References (37)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25 (Pubitemid 44420743)
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5 (Pubitemid 32424106)
3. Minin o BAM, Murphy SL, Jiaquan X, et al. Deaths: final data for 2008. Natl Vital Stat Rep 2011;59:1-157
4. Miyazaki S, Ito T, Suwa M, et al. Role of transesophageal echocardiography in the prediction of thromboembolism in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J 2001;65:874-8
5. CET Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989;46:727-43
6. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
7. Fuster V, Rydé n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice. Circ 2006;114:e257-354 (Pubitemid 44252297)
8. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur H J 2006;27:949-53
9. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
10. Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139-51
13. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883-91
14. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-2
15. Boehringer Ingelheim Pharmaceuticals, Inc. Highlights of Prescribing Information. PRADAXA-(dabigatran etexilate mesylate) capsules for oral use. Initial U.S. Approval: 2010. Ridgefield, Connecticut; 2011
16. Janssen Pharmaceuticals, Inc. Highlights of Prescribing Information. XARELTO (rivaroxaban) film-coated oral tablets. Initial U.S. Approval: 2011. Titusville, NJ; 2011
17. Centers for Medicare and Medicaid Services. Medicare Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing. 2010. http://www.medicarepaymentandreimbursement.com/2010/05/medicarepayment-for-e-m- code-99201.html. Accessed January 11, 2012
18. Consumer Price Index December 2010. USDL-11-0018. Bureau of Labor Statistics US Department of Labor. http://www.bls.gov/news.release/archives/cpi- 01142011.pdf. Accessed January 11, 2012
19. Chiong JR, Kim S, Lin J, et al. Evaluation of costs associated with Tolvaptanmediated length of stay reduction among heart failure patients with Hyponatremia in the US, based on the EVEREST Trial. J Med Econ 2012;15:1-9
20. Dasta JF, Chiong JR, Christian R, et al. Evaluation of costs associated with Tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 Trials. Hospit Pract 2012:40:1-8
21. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edn. Chest 2008;133(6 Suppl):546S-92S (Pubitemid 351892972)
22. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049-56 (Pubitemid 37430445)
23. Zimetbaum PJ, Thosani A, Yu H-T, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010;123: 446-53
24. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. New Engl J Med 2002; 347:1825-33 (Pubitemid 35417773)
25. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
26. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-8
27. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarinassociated hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401
28. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996;132:1095-100 (Pubitemid 26372785)
29. Melamed OC, Horowitz G, Elhayany A, et al. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011;17: 232-7
30. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
31. Berg AM. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:570, author reply 570-1
32. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Throm Haemost 2011;105: 908-19
33. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70
34. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY Trial. New Engl J Med 2010;363:1875-6
35. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). NDA 202439: XARELTO-(rivaroxaban) Tablets
36. Earnshaw SR, Scheiman J, Fendrick AM, et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011; 171:218-25
37. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86. (Pubitemid 350193368)